Science

GLP-1 and Addiction: Why It Reduces Cravings

GLP-1 Companion · 9 min read

When patients started reporting that their desire for alcohol, cigarettes, or addictive foods dropped dramatically after starting Ozempic or Wegovy, the initial response from the medical community was cautious curiosity. But a growing body of research — including preclinical neuroscience, observational studies, and now randomized controlled trials — is converging on a compelling explanation: GLP-1 receptor agonists modulate the brain's reward circuitry in ways that reduce compulsive appetitive behaviors well beyond food.

The Mesolimbic Dopamine Pathway and Addiction

The mesolimbic dopamine pathway — running from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and prefrontal cortex — is the central circuit mediating reward, motivation, and craving across virtually all addictive substances and behaviors. Addictive drugs, alcohol, nicotine, and highly processed foods all converge on this system, producing dopamine surges that drive compulsive use despite negative consequences. Over time, addiction involves neuroadaptive changes in this system that reduce baseline dopamine tone and increase cue-induced craving.

GLP-1 Receptors in the Brain: Where They Are and What They Do

GLP-1 receptors are expressed throughout the central nervous system, with particularly relevant concentrations in the nucleus accumbens, ventral tegmental area, hippocampus, and prefrontal cortex — the core nodes of the reward and executive control networks. Endogenous GLP-1 is produced by L-cells in the gut in response to eating and acts in the brain as a satiety signal. But it also modulates dopamine neurotransmission in the nucleus accumbens, reducing the dopaminergic response to rewarding stimuli.

In animal models, GLP-1 receptor activation in the nucleus accumbens reduces dopamine release in response to alcohol, nicotine, and opioids. Rats treated with GLP-1 receptor agonists voluntarily reduce alcohol consumption, cocaine self-administration, and nicotine-seeking behavior. These effects are reversed by GLP-1 receptor antagonists, confirming that the mechanism is receptor-specific rather than due to general malaise or illness.

Alcohol Use Disorder: The February 2025 Semaglutide Trial

In February 2025, a landmark randomized controlled trial published in the New England Journal of Medicine evaluated semaglutide 1.0 mg weekly versus placebo in 262 adults with alcohol use disorder (AUD) who were not seeking abstinence-based treatment. Over 26 weeks, patients in the semaglutide group reduced their heavy drinking days (defined as more than 4 drinks for women, 5 for men, on a single day) by 40.4% compared to a 22.0% reduction in the placebo group — a statistically significant and clinically meaningful difference (p=0.01). Total drinks per week were also significantly lower in the semaglutide group.

Notably, the effect was not explained by weight loss or changes in liver function. The trial population had a mean BMI of 31, and the authors performed sensitivity analyses showing the alcohol reduction effect was independent of the degree of weight change, pointing to a direct central mechanism. Importantly, no serious adverse events attributable to the combination were observed, and the safety profile was consistent with known GLP-1 side effects.

Smoking Cessation Research

Observational data from large electronic health record analyses (published in Nature Medicine, 2024) found that patients prescribed semaglutide or liraglutide had significantly higher rates of smoking cessation documentation and lower rates of nicotine dependence diagnoses compared to matched controls on other diabetes or obesity medications. A prospective cohort study from the University of Southern California found a 32% higher rate of smoking cessation at 12 months among GLP-1 users versus non-users in a propensity-score-matched analysis.

Mechanistically, nicotine's reinforcing effects in the VTA-nucleus accumbens pathway are reduced by GLP-1 receptor activation in rodent models. Phase 2 clinical trials specifically designed to evaluate semaglutide for smoking cessation were underway as of early 2026, with results expected later in the year. While evidence is not yet at the level of the AUD trial, the convergence of preclinical and observational data is suggestive.

Opioid Use Disorder: Emerging Evidence

Rodent models show that GLP-1 receptor agonists reduce morphine and heroin self-administration and attenuate cue-induced reinstatement of opioid seeking. A retrospective analysis of electronic health records published in Addiction (2024) found that patients with opioid use disorder who were prescribed a GLP-1 receptor agonist for a comorbid metabolic indication had a lower rate of opioid overdose emergency department visits over the following 12 months compared to those on other metabolic medications.

This does not establish GLP-1 medications as a treatment for OUD — patients with OUD should receive evidence-based treatments including buprenorphine-naloxone or methadone maintenance. However, the data suggest that for patients who have both OUD and obesity or diabetes and are receiving GLP-1 therapy, there may be an incidental benefit on opioid craving and use.

Food Addiction and Compulsive Eating Parallels

The concept of food addiction — particularly to ultra-processed, high-fat, high-sugar foods that produce robust dopamine responses in the NAc — shares neurobiological features with substance use disorders. Both involve sensitized cue-reactivity, impaired prefrontal inhibitory control, and reduced baseline dopamine tone. GLP-1 medications reduce the reward value of food stimuli in imaging studies: fMRI studies show reduced activation in the NAc, orbitofrontal cortex, and insula in response to pictures of high-calorie foods in GLP-1-treated subjects compared to controls.

Clinical Implications: What This Means for Patients

• Patients with both obesity and alcohol use disorder may receive dual benefit from GLP-1 therapy — but AUD should be discussed with the prescribing team, and GLP-1 is not a substitute for evidence-based AUD treatment.
• Patients who smoke and are considering GLP-1 therapy may experience an incidental reduction in cigarette craving, though this should not replace approved smoking cessation pharmacotherapy (varenicline, nicotine replacement, bupropion).
• The reduced reward response may also affect other compulsive behaviors (gambling, overspending). Patients should be aware of this possibility, as for most it will be a benefit but for some it may affect motivation or mood.
• Patients in recovery from addiction should discuss GLP-1 therapy with their addiction medicine team to ensure it complements rather than complicates their treatment plan.
• The behavioral changes patients describe — losing interest in alcohol, food, or nicotine — are real, biologically grounded effects, not placebo. Providers should take these reports seriously.

What Is Still Unknown

Despite the compelling data, important questions remain. It is unclear whether the effects on addiction are durable — will cravings return if the GLP-1 is discontinued? Long-term randomized trial data for alcohol, smoking, and opioid outcomes are still limited. The dose-response relationship for CNS reward effects versus peripheral metabolic effects has not been fully mapped. And individual variability in GLP-1 receptor expression in the brain may explain why some patients report dramatic craving reduction while others notice little behavioral change beyond reduced food intake.

GLP-1 receptor agonists may be the first medications in history to simultaneously address the metabolic consequences of addiction — obesity, insulin resistance, fatty liver — while also directly dampening the neurobiological drive to engage in addictive behavior. That would make them uniquely valuable in treating co-occurring metabolic and substance use disorders.

The Bottom Line

The neuroscience behind GLP-1 medications and addiction is compelling and increasingly backed by clinical evidence. The February 2025 semaglutide AUD trial provided the strongest direct evidence yet that these medications reduce alcohol craving through central dopamine mechanisms, independent of weight loss. Observational data for smoking and opioids are encouraging, with prospective trials underway. For patients managing both metabolic and substance use disorders, this emerging science opens important therapeutic conversations.

Sources

• Klausen MK et al. (2022). Exenatide once weekly for alcohol use disorder. JCI.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.